Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Wisconsin: - Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Froedtert and MCW Moorland Reserve Health Center — New Berlin, Wisconsin
- Drexel Town Square Health Center — Oak Creek, Wisconsin
- Froedtert West Bend Hospital/Kraemer Cancer Center — West Bend, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Wisconsin: - Research Site — Milwaukee, Wisconsin
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in Wisconsin: - Site #0141 — Madison, Wisconsin
- Site #0157 — Madison, Wisconsin
- Site # 0153 — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Wisconsin: - Medical College of Wisconsin - Froedtert Hospital Cancer Center — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Johnson Creek — Johnson Creek, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
Phase 2 Recruiting NIH
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Wisconsin: - ProHealth D N Greenwald Center — Mukwonago, Wisconsin
- ProHealth Oconomowoc Memorial Hospital — Oconomowoc, Wisconsin
- ProHealth Waukesha Memorial Hospital — Waukesha, Wisconsin
- UW Cancer Center at ProHealth Care — Waukesha, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Wisconsin: - Local Institution - 2145 — Appleton, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Wisconsin: - University of Wisconsin- Madison — Madison, Wisconsin
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Wisconsin: - UW Health Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
This is a prospective, randomized, open-label, two-arm phase 2 trial that will evaluate whether the use of Pulsed Low-Dose-Rate radiation technique, as compared to standard radiation, is associated with reduced rates of clinically signific…
Sponsor: Medical College of Wisconsin
NCT ID: NCT06906887
Sites in Wisconsin: - Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Wisconsin: - Exelixis Clinical Site #33 — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in Wisconsin: - Research Site — Milwaukee, Wisconsin
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield — Brookfield, Wisconsin
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
Recruiting Industry
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Sponsor: Tempus AI
NCT ID: NCT06163534
Sites in Wisconsin: - ThedaCare — Appleton, Wisconsin
NA Recruiting Academic/Other
This study is a randomized trial examining the impact of expiratory muscle strength training (EMST) on maintenance of safe and efficient oropharyngeal swallow function in persons with cancer of the head and neck (HNCA) undergoing treatment…
Sponsor: University of Wisconsin, Milwaukee
NCT ID: NCT03916809
Sites in Wisconsin: - University of Wisconsin Milwaukee — Milwaukee, Wisconsin
- Froedtert Hospital — Milwaukee, Wisconsin
NA Recruiting Academic/Other
The goal of this clinical trial is to study whether researchers can create a patient-specific tumor system, called a culture vessel, in a timely manner and determine if it can predict how someone will respond to a specific therapy. Partici…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT07343596
Sites in Wisconsin: - University of Wisconsin - Madison — Madison, Wisconsin